• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » MassDevice EuroPCR 2018 Roundup » Page 2

MassDevice EuroPCR 2018 Roundup

May 22, 2018 By Fink Densford

Abbott touts reduced major adverse cardiac events in 5-year PressureWire study

Abbott logo

Abbott (NYSE:ABT) today released five-year results from the Fame 2 study exploring the benefits of heart stent procedures guided by the company’s PressureWire fractional flow reserve diagnostic tool, touting reduced major adverse cardiac events.

Researchers in the study analyzed data from 733 patients with stable coronary artery disease who had significant blockages or narrowing of the arteries as determined by FFR, the company said.

Results from the trial indicated a 13.9% of patients in the FFR-guided PCI group experienced a major adverse cardiac event, significantly less than the 27% MACE rate reported in the medical therapy group. Abbott said that the lower rate of MACE was driven by reduced urgent revascularization.

Patients in the FFR-guided PCI cohort experienced fewer heart attacks than the non FFR-guided cohort, at 8.1% versus 12%, respectively. Rates of all-cause mortality were 5.1% for the FFR cohort versus 5.2% in the medical therapy only group, Abbott reports.

“For the first time, a study has shown that patients with stable coronary artery disease who received a stent guided by an FFR diagnostic had a benefit over medical therapy alone, including fewer heart attacks and needs for urgent revascularization. Data from this study confirm the importance of FFR-guided stenting decisions combined with medical therapy over medical therapy alone,” principal investigator Dr. Bernard De Bruyne of Belgium’s Cardiovascular Center Aalst, Onze Lieve Vrouw Ziekenhuis said in a press release.

Abbott also presented data from a second study exploring the company’s resting full-cycle ratio diagnostic test, which uses a different approach to FFR that analyzes the heart at rest instead of during stress.

A study of 672 coronary artery narrowings from 504 patients aimed to compare the RFR test with instant wave-free radio diagnostics, also used to measure blood flow in resting hearts.

Data from the study showed that RFR was highly correlated to iFR and diagnostically equivalent to 1%, Abbott said. The RFR technlogy is currently pending an FDA 510(k) clearance and CE Mark approval in the European Union.

“We’re committed to bringing life-saving technologies to people with heart disease including diagnostic tools that help doctors make treatment decisions, which lead to better outcomes for patients. These results continue to support that measuring blood flow prior to implanting a stent is an effective way to help doctors determine which vessels to treat, and can improve patient outcomes over medical therapy alone,” Abbott vascular biz chief medical officer Dr. Charles Simonton said in a prepared statement.

Next >>

Pages: Page 1 Page 2 Page 3

Filed Under: Cardiac Implants, Cardiovascular, Clinical Trials, Replacement Heart Valves Tagged With: Abbott, Edwards Lifesciences, Esaote

In case you missed it

  • Leading Medical UX Trends
  • Ex-Acclarent execs fined $1.5M in off-label marketing case
  • CDER head Woodcock to lead FDA for now
  • Prosecutors want to present evidence of Elizabeth Holmes’ quest for wealth and fame
  • TransEnterix raises more than $31M in stock offering
  • Boston Scientific launches WaveWriter Alpha spinal cord stim
  • What’s next for the FDA and for Stephen Hahn?
  • Apple magnetic charger, smartwatch may deactivate Medtronic ICD
  • Medicare to cover breakthrough devices
  • FDA debuts plan for AI-based Software as a Medical Device
  • EU allows remote audits for medical devices during pandemic
  • Smith+Nephew sees Movemedical automating inventory for its sales people
  • BD stock up on Street-beating preliminary quarterly revenue numbers
  • Boston Scientific’s preliminary Q4 results show 6.8% revenue decline
  • BREAKING: Steris to acquire Cantel Medical in $4.6B deal
  • FDA grants EUA for RapCov rapid COVID-19 antibody test
  • Former Corindus CEO Toland joins robotic `micro’ surgical startup

RSS From Medical Design & Outsourcing

  • Reflow Medical launches low-profile reinforced support catheters
    Reflow Medical today announced it has launched its Reflow Spex Low Profile reinforced support catheters. The Spex LP catheters are designed to provide the lowest profile tip to access and cross the tightest and most complex lesions with a supportive system. They come in 0.014 in. and 0.018 in. sizes and can be combined with… […]
  • CDER head Woodcock to lead FDA for now
    FDA veteran Dr. Janet Woodcock has been tapped as interim FDA commissioner by the Biden administration, according to published reports. An article by BioCentury also said that former FDA commissioner David Kessler, who had been mentioned as a possible replacement for current commissioner Stephen Hahn, will be a consultant to the agency but will not… […]
  • What’s next for the FDA and for Stephen Hahn?
    Outgoing FDA commissioner Stephen Hahn says he needs some time to reflect on his future after leading the FDA for a little over a year. It’s hard to blame him. Hahn’s brief tenure at FDA has been rocky, to say the least. (News of his temporary replacement broke on Thursday, when the incoming Biden administration… […]
  • Medicare to cover breakthrough devices
    FDA-designated breakthrough devices will have Medicare coverage the same day they are approved, under a final rule issued this week by the Centers for Medicare and Medicaid Services (CMS). The Medicare Coverage of Innovative Technology (MCIT) rule will provide national Medicare coverage as early as the same day as FDA market authorization for breakthrough devices… […]
  • FDA debuts plan for AI-based Software as a Medical Device
    The FDA today released its first plan to regulate artificial intelligence/machine learning (AI/ML)-based Software as a Medical Device (SaMD). The plan is a response to feedback received from the agency’s April 2019 discussion paper, “Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning-Based Software as a Medical Device.” It outlines five actions that the FDA… […]
  • EU allows remote audits for medical devices during pandemic
    The European Union has announced that it will temporarily allow remote audits of medical devices and in vitro diagnostics under the new regulations (MDR IVDR), set to go into effect on May 2021 and 2022 respectively. In a document published Monday, the European Commission agreed with industry and notified bodies that the ongoing COVID-19 pandemic… […]
  • Apple magnetic charger, smartwatch may deactivate Medtronic ICD
    A new study in the Heart Rhythm Journal showed a magnetic charger for the iPhone 12 was able to deactivate a Medtronic implantable cardioverter defibrillator (ICD). The iPhone 12 has a circular array of magnets deployed around a central charging coil, making it compatible with the company’s wireless “MagSafe” accessories, according to the study published… […]
  • BREAKING: Steris to acquire Cantel Medical in $4.6B deal
    Steris (NYSE:STE) announced today that it will acquire Cantel Medical (NYSE:CMD) for $4.6 billion — a major merger in the infection prevention space. The deal is expected to close by June 30, pending customary closing conditions, regulatory approvals and an OK by Cantel shareholders. News of the merger comes a month and a half after Steris closed… […]
  • How Abbott stayed two steps ahead of COVID-19
    Developing a fast COVID-19 that resembled a pregnancy test and building two factories to boost productions — those were but two of the quick-thinking actions that Abbott (NYSE:ABT) officials took in the early months of a deadly coronavirus pandemic. Abbott began tracking the virus in China at the end of 2019 and into early 2020. By February,… […]
  • BREAKING: Big medtech suspends political contributions in wake of Electoral College vote
    Just as they lined up to condemn last week’s attack on the U.S. Capitol, major medtech companies are suspending political contributions because of 147 federal lawmakers’ refusal to acknowledge the Electoral College win by President-elect Joe Biden and Vice President-elect Kamala Harris. Boston Scientific announced on Sunday that it has chosen to temporarily suspend its… […]
  • Neurofeedback could help prostheses feel lighter: Here’s how
    Researchers at ETH Zurich have developed a prosthesis system that connects to the body’s nervous system to help amputees perceive a prosthetic weight as lower. The prosthesis system provides feedback to the wearer using electrodes implanted in the thigh that are connected to the leg nerves. Information from the tactile sensors under the sole of… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS